Physician profile
Amy L Lowe
NPI 1912259805
$7,179.59
in general payments reported to CMS, 2019-2025
23 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $1,432 · 2023: $1,413 · 2024: $1,685 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,262.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,042.08 | 2021-2025 | |
| Genzyme Corporation | $1,079.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $465.16 | 2021-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $441.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $440.40 | 2021-2025 | Dupixent |
| Incyte Corporation | $426.70 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $309.48 | 2024-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $244.57 | 2023-2025 | Zoryve |
| Organon LLC | $241.67 | 2025 | Vtama |
| Lilly USA, LLC | $225.23 | 2022-2025 | Ebglyss, Taltz |
| Verrica Pharmaceuticals INC. | $225.17 | 2023-2025 | Ycanth |
| Galderma Laboratories, L.P. | $212.15 | 2022-2025 | Aklief, Epsolay |
| Janssen Biotech, INC. | $187.57 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $166.85 | 2024-2025 | |
| Ucb, INC. | $77.41 | 2024-2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.41 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Mayne Pharma Commercial LLC | $61.87 | 2023-2025 | |
| Amgen INC. | $58.99 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $54.61 | 2022-2024 | Sotyktu |
| Botanix Sb INC | $51.86 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.08 | 2023-2024 | Spevigo, Cyltezo |
| Biofrontera INC. | $36.78 | 2021-2022 | |
| Dermavant Sciences, INC. | $25.98 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.